There are an estimated 20 million Americans and over 140 million people globally suffering from Long COVID. In fact, more than four in 10 people — 43% — said in a recent TIPP poll that they knew someone with long Covid, a condition where symptoms persist for several weeks or longer. The Centers for Disease Control describes post-COVID conditions as ongoing or new symptoms occurring a month or more after a COVID-19 infection. It is estimated that between 10% to 30% of people who had COVID-19 may experience long COVID.
There’s currently no single test that can determine if someone has long COVID. And unlike being able to find out if the Epstein-Barr virus has reactivated, there is presently no blood test on the market that can determine if the SARS-CoV-2 is still active in someone with long COVID. Instead, physicians rely on a battery of tests such as the complete blood count (CBC), electrolytes, metabolites, hepatic function panels, cardiac biomarkers, thyroid panels and D-dimer to determine the overall health of the patient with long COVID.
Long Covid is particularly complicated because there’s no set list of symptoms. The Centers for Disease Control and Prevention notes a wide array of ongoing health problems that could include fatigue, shortness of breath, neurological and digestive symptoms as well as joint or muscle pain.
The U.S. Government Accountability Office estimates up to 23 million people in the U.S. have long COVID. Research is still in its infancy, though. Not every COVID-19 case is diagnosed. Further, symptoms of long Covid vary and manifest themselves differently in each person.
COMPANIES ADDRESSING LONG COVID
As the next big global health crisis severely impacts worker disability, worker productivity and negatively impacting gross domestic product, large companies are shying away from treating the condition. Smaller companies working on testing and/ or treatments include; Tonix Pharmaceuticals (Nasdaq: TNXP), Regencell Bioscience (Nasdaq: RGC), Wave BioPharma (Nasdaq: FWBI), Ampio Pharmaceuticals (NYSE: AMPE), and Aim ImmunoTech (NYSE: AIM). Ampio, Regencell and Tonix include long Covid treatments in their pipelines. First Wave is working on gastrointestinal side effects of Covid-19. Aim is testing out a treatment for Covid-19 patients with cancer. Humanetics is looking at lung injuries in Covid-19 patients.
However, the companies making the most progress in the space are Axcella Therapeutics (AXLA) and Todos Medical (OTCMKTS: TOMDF). Todos (TOMDF) is particularly interesting because there is currently no test for Long COVID Axcella Therapeutics (Nasdaq: AXLA) is currently developing a treatment for Long COVID through clinical programs utilizing AXA1125. It has completed the Phase 2A trial of Long COVID in collaboration with Oxford University. “The results were extremely encouraging and showed that administration of AXA1125 to patients significantly reduced mental and physical fatigue,” said Bill Hinshaw, President and Chief Executive Officer of Axcella.
Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, through its Alpharetta, Georgia-based CLIA/CAP certified lab gained in the acquisition of Provista Diagnostics, Inc. is currently performing Long Covid Panel analyses. Utilizing Tollovid the company is seeking to address Long Covid with testing, treatment and dietary supplement solutions.
TOMDF is compiling 35+ individual case studies with PASC participants as their physicians monitor their symptoms and progress on Tollovid™ over 30, 60, and 90 day periods. The company is also conducting a randomized, observer blinded, non-exposure control study to evaluate the safety of TollovidTM and Tollovid’s effects on the structure/function of the immune system in subjects with Long COVID.
A few highlights from TOMDF’s studies include:
- 100% of Acute COVID-19 respondents reported a decrease in Acute COVID Symptoms.
- 93.7% of Short Long COVID respondents reported a decrease in Short Long COVID Symptoms.
- 41.6% of Chronic Long COVID respondents reported a decrease in Long Long COVID Symptoms.
- 83% of Acute COVID-19 respondents reported that they were happy with their results with Tollovid.
- 87.5% of Short Long COVID respondents reported that they were happy with their results with Tollovid.
- 41.6% of Chronic Long COVID respondents reported that they were happy with their results with Tollovid.
- 72.7% of Acute COVID-19 respondents reported a decrease in fatigue.
- 91.6% of Short Long COVID respondents reported a decrease in fatigue.
- 50% of Chronic Long COVID respondents reported a decrease in fatigue.
Investors looking to profit from companies fighting Long COVID must look to the smaller companies focused on the condition while their larger counterparts zero in on Acute COVID. Of these companies, one of the most complete options is TOMDF and its Tollovid treatment which also includes the crucial component of testing for Long COVID.
Start your research today.
Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quotes; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled. CapitalGainsReport ‘CGR’ is responsible for the production and distribution of this content. CGR is not operated by a licensed broker, a dealer, or a registered investment adviser. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. CGR authors, contributors, or its agents, may be compensated for preparing research, video graphics, and editorial content. CGR is compensated one thousand eight hundred dollars monthly via wire transfer by Todos Medical to produce and syndicate content related to TOMDF. As part of that content, readers, subscribers, and website viewers, are expected to read the full disclaimers and financial disclosures statement that can be found on our website.